John W. Higuchi

CIK: 0001579891

Transaction Breakdown

Open Market Buys (P)4 (66.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LPCN

Lipocine Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

LPCN
Lipocine Inc.
Sep 30, 2026
Purchase(P)
Direct
16K shares at avg. $2.23$36K
LPCN
Lipocine Inc.
Sep 29, 2026
Purchase(P)
Direct
9K shares at avg. $2.15$19K
LPCN
Lipocine Inc.
Jun 3, 2026
Award(A)
Common Stock (Right to Buy)
Direct
1.8K shares at avg. $2.19-
LPCN
Lipocine Inc.
Apr 7, 2026
Purchase(P)
Direct
40K shares at avg. $2.03$81K
LPCN
Lipocine Inc.
Apr 6, 2026
Purchase(P)
Direct
123K shares at avg. $2.05$252K
LPCN
Lipocine Inc.
Jun 4, 2025
Award(A)
Common Stock (Right to Buy)
Direct
1.8K shares at avg. $3.20-

		Type	Shares	Price		Ownership
Sep 30, 2026	LPCN Lipocine Inc.	Purchase(P)	15,970	$2.23	$35,613	Direct
Sep 29, 2026	LPCN Lipocine Inc.	Purchase(P)	9,037	$2.15	$19,430	Direct
Jun 3, 2026	LPCN Lipocine Inc.	Award(A) Common Stock (Right to Buy)	1,764	$2.19	-	Direct
Apr 7, 2026	LPCN Lipocine Inc.	Purchase(P)	40,000	$2.03	$81,200	Direct
Apr 6, 2026	LPCN Lipocine Inc.	Purchase(P)	123,000	$2.05	$252,150	Direct
Jun 4, 2025	LPCN Lipocine Inc.	Award(A) Common Stock (Right to Buy)	1,764	$3.20	-	Direct

1-6 of 6 transactions

About Higuchi John W.

Higuchi John W. (SEC CIK 0001579891) files insider reports with the SEC as Director of Lipocine Inc. (LPCN).

Signal8 holds 5 ownership filings by Higuchi John W., all Form 4s, filed between Jun 5, 2025 and Oct 1, 2026. Those filings report 6 transactions, from Jun 4, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Higuchi John W.'s filings is in SALT LAKE CITY, UT.

Recent filings by Higuchi John W.

Sep 30, 2026: Open-market purchase of LPCN shares (Form 4, code P).
Sep 29, 2026: Open-market purchase of LPCN shares (Form 4, code P).
Jun 3, 2026: Grant or award of LPCN derivative securities (Form 4, code A).
Apr 7, 2026: Open-market purchase of LPCN shares (Form 4, code P).
Apr 6, 2026: Open-market purchase of LPCN shares (Form 4, code P).

Other insiders filing for Lipocine Inc. (LPCN)

Grissinger Michael, Director
Jene Jill M., Director
Ono Richard Dana, Director
Patel Mahesh V., Chief Executive Officer
Fogarty Krista, Principal Accounting Officer
Papapetropoulos Spyros, Director

How to read Form 4 transaction codes